Home » Stocks » IMUX

Immunic, Inc. (IMUX)

Stock Price: $9.17 USD 0.02 (0.22%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 241.76M
Revenue (ttm) n/a
Net Income (ttm) -70.06M
Shares Out 26.25M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $9.17
Previous Close $9.15
Change ($) 0.02
Change (%) 0.22%
Day's Open 9.22
Day's Range 9.04 - 9.39
Day's Volume 89,007
52-Week Range 8.64 - 28.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

1 week ago - PRNewsWire

Word of a new share issue made investors feel queasy.

2 weeks ago - The Motley Fool

Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The g...

2 weeks ago - Benzinga

NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

2 weeks ago - PRNewsWire

NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

2 weeks ago - PRNewsWire

NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

2 weeks ago - PRNewsWire

The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis.  In...

4 weeks ago - Benzinga

NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

4 weeks ago - PRNewsWire

NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

1 month ago - PRNewsWire

NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

1 month ago - PRNewsWire

NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

1 month ago - PRNewsWire

NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammato...

2 months ago - PRNewsWire

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Other stocks mentioned: CVAC, INO
3 months ago - Benzinga

NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamm...

3 months ago - PRNewsWire

NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

3 months ago - PRNewsWire

NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology ther...

3 months ago - PRNewsWire

Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst:...

4 months ago - Benzinga

A simple yet effective way to screen stocks for investment ideas is to look at what the insiders are doing, and to keep an eye out for insider buying. The insiders are the people in a company who have a...

Other stocks mentioned: ASAN, BWEN, GE, KNSL, TUP
4 months ago - InvestorPlace

NEW YORK, March 2, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

4 months ago - PRNewsWire

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease char...

5 months ago - Benzinga

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with moderate CO...

5 months ago - Benzinga

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

6 months ago - PRNewsWire

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

7 months ago - PRNewsWire

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

8 months ago - PRNewsWire

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

8 months ago - PRNewsWire

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

8 months ago - PRNewsWire

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

8 months ago - PRNewsWire

LUXEMBOURG and GRÄFELFING, Germany and NEW YORK, Oct. 20, 2020 /PRNewswire/ -- The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing ...

9 months ago - PRNewsWire

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

10 months ago - PRNewsWire

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

10 months ago - PRNewsWire

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc.

10 months ago - PRNewsWire

NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Immunic, Inc.

10 months ago - PRNewsWire

An analyst says buy.

11 months ago - The Motley Fool

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Immunic, Inc.

11 months ago - PRNewsWire

NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Immunic, Inc.

11 months ago - PRNewsWire

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Immunic Inc (NASDAQ: IMUX) shares are surging following a positive clinical readout.

11 months ago - Benzinga

NEW YORK, July 30, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

11 months ago - PRNewsWire

NEW YORK, July 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

1 year ago - PRNewsWire

NEW YORK, July 27, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

1 year ago - PRNewsWire

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, BSGM, CYDY, EIGR, GILD, PFE ...
1 year ago - Seeking Alpha

NEW YORK, June 22, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

1 year ago - PRNewsWire

NEW YORK, June 15, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

1 year ago - PRNewsWire

Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intes... [Read more...]

Industry
Biotechnology
CEO
Daniel Vitt
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
IMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 57.00, which is an increase of 521.59% from the latest price.

Price Target
$57.00
(521.59% upside)
Analyst Consensus: Buy